Digital Content 
NEWS #PharmaBuzz
05 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/05/3094267/0/en/Avadel-Pharmaceuticals-Receives-Orphan-Drug-Designation-from-FDA-for-LUMRYZ-sodium-oxybate-for-Extended-Release-Oral-Suspension-for-the-Treatment-of-Idiopathic-Hypersomnia.html
29 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/29/3090714/0/en/Avadel-Pharmaceuticals-to-Present-New-Data-on-LUMRYZ-sodium-oxybate-For-Extended-Release-Oral-Suspension-at-SLEEP-2025.html
27 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/girard-sharp-llp-and-motley-rice-llc-announce-proposed-settlements-in-in-re-xyrem-sodium-oxybate-antitrust-litigation-302463749.html
17 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/17/3063328/0/en/Avadel-and-nference-Announce-Publication-of-Real-World-Data-on-Sodium-Oxybate-Treatment-Patterns-in-the-Journal-of-Clinical-Neuroscience.html
09 Apr 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/jazz-pharma-pay-145-million-settle-narcolepsy-drug-antitrust-case-2025-04-08/
17 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/17/2964979/0/en/Avadel-Pharmaceuticals-Announces-FDA-Approval-of-LUMRYZ-sodium-oxybate-Extended-Release-Oral-Suspension-CIII-for-the-Treatment-of-Cataplexy-or-Excessive-Daytime-Sleepiness-in-Patie.html
Share 